L26/P-590 Treatment discontinuation in IVF: an in-depth characterization across different settings
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.922 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von F. Battista und 14 weiteren Autor:innen.
Abstract (Originalsprache)
Study question What is the prevalence, timing and determinants of treatment discontinuation and non-conversion in IVF across different settings? Summary answer Treatment discontinuation is frequent and multifactorial throughout the IVF journey, increasing among repeated cycles (>3 cycles), influenced by patient prognosis, private/public setting and treatment burden. What is known already IVF treatment discontinuation is widely recognized as a relevant limitation in the evaluation of treatment effectiveness. Previous studies have reported substantial discontinuation rates, mainly attributed to psychological distress, poor prognosis and economic burden. However, definitions of treatment discontinuation remain heterogeneous and little attention has been paid to early phases of the ART journey, such as the failure to initiate treatment after the first clinical consultation. Moreover, differences between public and private settings and their impact on treatment continuity are still poorly explored. Study design, size, duration Systematic review conducted according to PRISMA guidelines. A comprehensive literature search of main databases was performed until June 2025. Eligible studies reported IVF treatment discontinuation and provided information on care setting (public vs private), country or geographic area, prevalence, and associated factors, regardless of treatment stage. No restrictions were applied on study design or setting. Participants/materials, setting, methods Studies including couples undergoing IVF in public or private settings were analysed. Data were extracted on patient characteristics, particularly maternal age, treatment discontinuation prevalence, timing across treatment cycles, associated clinical, psychological and organizational factors, and phase of treatment interruption. Study quality was assessed using the Newcastle–Ottawa Scale and ROBINS-I, according to study design. Main results and the role of chance A total of 55 studies published between 1984 and 2025 were included, showing substantial heterogeneity in definitions and reporting of treatment discontinuation. Treatment discontinuation emerged as a frequent and structural phenomenon throughout the IVF journey. It was reported as being higher in the public setting (36 studies; N = 89,349/160,292 patients, 56%) versus the private settings (19 studies; N = 7,093/18,120 patients, 39%; p < 0.001). In both settings, discontinuation increased with the number of cycles, with approximately half of patients discontinuing the treatment after the third cycle or later (14 studies). Importantly, a relevant proportion of patients did not initiate any treatment after the first consultation. This early loss was captured through the novel operational concept of non-conversion rate, introduced in this review to describe a previously underexplored phase of the IVF journey, and appeared consistently higher in private (4 studies; N = 931/4,103 patients, 23%) than in public settings (7 studies; N = 471/3,973 patients,12%). Factors influencing treatment discontinuation were consistently multifactorial. They include medical factors (poor prognosis, repeated failures, diminished ovarian reserve) as assessed in 43 studies, demographics (maternal age) as reported in 28 studies, psychological factors as reported in 39 studies, economic burden as reported in 23 studies, logistical determinants as reported in 41 studies. Limitations, reasons for caution Marked heterogeneity in definitions, study design and outcome reporting limits comparability across studies. Treatment discontinuation was usually assessed at single-centre level, not counting patient transfer between centers. The concept of non-conversion rate lacks international consensus. Further studies are needed to statistically assess the relative contribution of factors influencing treatment discontinuation. Wider implications of the findings Treatment discontinuation and non-conversion should be considered key outcomes in IVF. Standardized definitions and patient-centred, personalized and time-efficient strategies appear promising in improving treatment continuity. Multicycle approaches, including DuoStim, may help reduce treatment burden in poor-prognosis patients, although further prospective studies are needed to assess their impact on drop-out reduction. Trial registration number No
Zitieren
APA
Battista, F., Perone, V., Incognito, G., Taggi, M., Innocenti, F., Ruffa, A., Pittana, E., Ettore, G., Ettore, C., Colamaria, S., Rienzi, L., Nappi, R., Ubaldi, F., Cimadomo, D., & Vaiarelli, A. (2026). L26/P-590 Treatment discontinuation in IVF: an in-depth characterization across different settings. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.922
Vancouver
Battista F, Perone V, Incognito G, Taggi M, Innocenti F, Ruffa A, et al. L26/P-590 Treatment discontinuation in IVF: an in-depth characterization across different settings. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.922
BibTeX
@article{Battista2026,
author = {Battista, F. and Perone, V. and Incognito, G.G. and Taggi, M. and Innocenti, F. and Ruffa, A. and Pittana, E. and Ettore, G. and Ettore, C. and Colamaria, S. and Rienzi, L. and Nappi, R.E. and Ubaldi, F.M. and Cimadomo, D. and Vaiarelli, A.},
title = {L26/P-590 Treatment discontinuation in IVF: an in-depth characterization across different settings},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.922}
}
EUVIMED